N6-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands

被引:100
作者
Volpini, R
Costanzi, S
Lambertucci, C
Taffi, S
Vittori, S
Klotz, KN
Cristalli, G
机构
[1] Univ Camerino, Dipartimento Sci Chim, I-62032 Camerino, Italy
[2] Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany
关键词
D O I
10.1021/jm0109762
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of N-6-alkyl-2-alkynyl derivatives of adenosine (Ado) have been synthesized and evaluated for their affinity at human A(1), A(2A), and A(3) receptors and for their potency at A(2B) adenosine receptor subtypes. The corresponding 2-(1-alkynyl) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) and Ado are used as reference compounds. Binding studies demonstrated that the activities of 2-alkynylAdos were slightly increased for the adenosine A, receptor and slightly decreased for both A(3) and A(2B) subtypes compared to those of their corresponding NECA derivatives, whereas the A(2A) receptor affinities of the two series of nucleosides were similar. The presence of a methyl group on N-6 of the 2-alkynyladenosines, inducing an increase in affinity at the human A(3) receptor and a decrease at the other subtypes, resulted in an increase in A(3) selectivity. In particular, 2-phenylethynyl-N-6-methylAdo (8b) showed an A(3) affinity in the low nanomolar range (K-i(A(3)) = 3.4 nM), with a A(1)/A(3) and A(2A)/A(3) selectivity of about 500 and 2500, respectively. These findings motivated us to search for the preparation of new selective radioligands for the A(3) subtype; hence, a procedure to introduce a tritiated alkylamino group in these molecules was carried out. As far as the potency at the A(2B) receptor, the type of 2-alkynyl chain and the presence of the ethylcarboxamido group on the sugar seem to be very important; in fact, the (S)-2-phenylhydroxypropynylNECA [(S)-PHPNECA, 1e, EC50(A(2B)) = 0.22 muM] proved to be one of the most potent A(2B) agonist reported so far. On the other hand, the (S)-2-phenylhydroxypropynyl-N-6-ethylAdo (9e, EC50(A(2B)) = 0.73 muM) showed a significantly increase of potency at the A(2B) subtype in comparison with the N-6-methyl, N-6-isopropyl, and the unsubstituted adenosine derivatives, although it resulted in being less potent than (S)PHPNECA (le, EC50(A(2B)) = 0.22 muM). These observations suggest that the introduction of an ethyl group in the N-6-position and an ethylcarboxamido substituent in the 4'-position of (S)2-phenylhydroxypropynyladenosine could lead to a compound endowed with high potency at the A(2B) receptor.
引用
收藏
页码:3271 / 3279
页数:9
相关论文
共 27 条
[1]   Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5′-N-ethyluronamide as A1 and A3 adenosine receptor agonists [J].
Baraldi, PG ;
Cacciari, B ;
de Las Infantas, MJP ;
Romagnoli, R ;
Spalluto, G ;
Volpini, R ;
Costanzi, S ;
Vittori, S ;
Cristalli, G ;
Melman, N ;
Park, KS ;
Ji, XD ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (17) :3174-3185
[2]   Novel N-6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A(3) adenosine receptors [J].
Baraldi, PG ;
Cacciari, B ;
Spalluto, G ;
Ji, XD ;
Olah, ME ;
Stiles, G ;
Dionisotti, S ;
Zocchi, C ;
Ongini, E ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :802-806
[3]   Why are A2B receptors low-affinity adenosine receptors?: Mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-(1-hexynyl) adenosine [J].
Beukers, MW ;
Den Dulk, H ;
Van Tilburg, EW ;
Brouwer, J ;
Ijzerman, AP .
MOLECULAR PHARMACOLOGY, 2000, 58 (06) :1349-1356
[4]   Adenosine receptor agonists: Synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA [J].
Camaioni, E ;
Di Francesco, E ;
Vittori, S ;
Volpini, R ;
Cristalli, G .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (12) :2267-2275
[5]   2-ALKYNYL DERIVATIVES OF ADENOSINE AND ADENOSINE-5'-N-ETHYLURONAMIDE AS SELECTIVE AGONISTS AT A2 ADENOSINE RECEPTORS [J].
CRISTALLI, G ;
ELEUTERI, A ;
VITTORI, S ;
VOLPINI, R ;
LOHSE, MJ ;
KLOTZ, KN .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (13) :2363-2368
[6]   2-ALKYNYL DERIVATIVES OF ADENOSINE-5'-N-ETHYLURONAMIDE - SELECTIVE A(2) ADENOSINE RECEPTOR AGONISTS WITH POTENT INHIBITORY ACTIVITY ON PLATELET-AGGREGATION [J].
CRISTALLI, G ;
VOLPINI, R ;
VITTORI, S ;
CAMAIONI, E ;
MONOPOLI, A ;
CONTI, A ;
DIONISOTTI, S ;
ZOCCHI, C ;
ONGINI, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (11) :1720-1726
[7]   2-ARALKYNYL AND 2-HETEROALKYNYL DERIVATIVES OF ADENOSINE-5'-N-ETHYLURONAMIDE AS SELECTIVE A(2A) ADENOSINE RECEPTOR AGONISTS [J].
CRISTALLI, G ;
CAMAIONI, E ;
VITTORI, S ;
VOLPINI, R ;
BOREA, PA ;
CONTI, A ;
DIONISOTTI, S ;
ONGINI, E ;
MONOPOLI, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) :1462-1472
[8]  
CRISTALLI G, 1996, PERSPECTIVES RECEPTO, P165
[9]   Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor [J].
Fishman, P ;
Bar-Yehuda, S ;
Ohana, G ;
Pathak, S ;
Wasserman, L ;
Barer, F ;
Multani, AS .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1452-1458
[10]   Adenosine receptor ligands: Differences with acute versus chronic treatment [J].
Jacobson, KA ;
vonLubitz, DKJE ;
Daly, JW ;
Fredholm, BB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (03) :108-113